Ballroom 3 at the Baltimore Convention Center was standing room only Tuesday afternoon at the annual meeting of the American Society of Gene & Cell Therapy. Several speakers took to the stage in succession to discuss ongoing efforts to improve adeno-associated virus purification and yield, aiming to improve both the safety and quality of these workhorse vectors of gene therapy.
Preliminary results for the year ended 31 December 2023
Oxford Biomedica Provides Update on CDMO Services Including New Comm Agreement
Board changes following transformation to pure-play CDMO business model
Update to Financial Guidance and 2023 Trading and Notice of Results
Oxford Biomedica completes acquisition of ABL Europe
Oxford Biomedica is hosting a free webinar to share clients success stories in viral vector manufacturing Oxford, UK “ 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and...
Business Update Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing)On...
Oxford Biomedica agreed to acquire French CDMO ABL Europe, a subsidiary of Institut Mérieux, for 15 million euros ($16 million) in a deal that will give the drugmaker expanded viral vector capabilities.
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica announces the signing of a sale and purchase agreement...